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307 Are the UK Cystic Fibrosis Trust recommendations for
bone health achievable?
J. Al-Siaidi1, A. Keele1, I. Sequeiros1, K. Bateman1. 1University Hospitals Bristol
NHS Foundation Trust, Bristol, United Kingdom
Objectives: Audit of current practice at the Bristol Adult CF Centre against the
2007 UK CF Trust recommendations in regard to dual-energy X-ray absorptiometry
(DEXA) scans, calcium intake, vitamin D status and bisphosphonate treatment.
Methods: A retrospective case note audit for patients that had an annual review in
2010. Data was compared with the 2007 UK CF Trust recommendations for bone
health.
Results: 106 patients were invited for annual review in 2010: 93 (88%) attended.
Of these 93 patients 84 (90%) had a DEXA scan within the last 3 years, 7 (8%) did
not attend, 1 (1%) refused and 1 (1%) scan was not ordered. Despite measures to
optimise bone health, 17 (20%) patients still met clinical criteria for bisphosphonate
treatment of whom 13 (15%) were receiving treatment. In 4 patients (5%) treatment
was delayed for clinical reasons. 7 patients (8%) were taking bisphosphonates that
no longer met the criteria.
Serum 25-OH vitamin D was measured in 86 patients (92%): 59 (69%) had a
level below the recommended 75 nmol/l. All patients had been prescribed vitamin
supplements appropriately. Poor adherence to vitamin therapy was identiﬁed in
11 patients (12%).
Calcium intake was assessed in 81 patients (87%): 38 (47%) had a calcium intake
below the recommended 1300mg/day even with ongoing dietetic support.
Conclusion: This audit has highlighted the challenges of meeting the UK CF Trust
recommendations relating to vitamin D status and calcium intake despite dietetic
advice and monitoring. It has also raised awareness that there are a small number
of patients receiving bisphosphonate treatment that may no longer be clinically
indicated.
308 Correction of low bone mass density in patients with cystic
ﬁbrosis
S. Sciuca1, O. Turcu1. 1State Medical and Pharmaceutical University, Pediatrics,
Chisinau, Moldova
Background: Bone disease is a common complication that progresses with age,
severity of lung damage and nutritional disorders in patients with cystic ﬁbro-
sis (CF).
Aim: To study the effect of calcium supplements and vitamin D on low bone mass
density (BMD) in patients with CF.
Materials and Methods: A group of 42 patients with CF was examined to
measure low BMD status and the effects of therapy. Chest deformation was found
in 1/3 of schoolchildren with CF and in two toddlers with a very severe disease
evolution. Children with CF were divided into two groups: ﬁrst group − 26 children
younger than 12 years, and the second − 21 children older than 12 years. Calcium
supplements with vitamin D were given to correct the low values of BMD in
children with CF. This study lasted for 3 months. The control group consisted
of 21 children with CF (8 children <12 years and 13 children >12 years) with
no calcium supplements for the period of this study. Quantitative ultrasound was
performed (Omnisense 7000P) and Z-score of BMD was assessed.
Results: Initial Z-score showed decreased values in both study groups: −2.83±0.44
SD in CF children <12 years and −3.61±0.50 SD in CF patients >12 years. The
level of initial Z-score in the control group were −2.73±0.51 SD (CF children
<12 years) and −3.82±0.62 SD (CF children >12 years). Three months of treatment
with calcium supplement produced an increase of Z-score to −2.44±0.47 SD in
children <12 years and to −2.85±0.49 SD in older patients comparative to the
control groups: −2.77±0.38 SD (p> 0.05) and −3.21±0.52 SD (p< 0.01).
Conclusion: Calcium supplements with vitamin D in CF patients have a beneﬁc
inﬂuence on BMD Z-score.
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Several risk factors of decreased bone mineral density (BMD) in cystic ﬁbrosis (CF)
children have been identiﬁed. The aim of the study was to deﬁne other determinants
of occurring abnormalities.
The study comprised 78 pancreatic insufﬁcient CF patients, with mild/moderate
lung disease, no liver involvement and diabetes mellitus, not taking systemic
steroids. Nutritional status (standardized body height and weight), lumbar BMD
(DEXA), pulmonary function (FEV1), serum vitamin D3, calcium intake and single
nucleotide polymorphism upstream of the lactase gene was assessed in all subjects.
In subjects with −13910C/C genotype (predisposing to adult-type hypolactasia), the
presence of lactose malabsorption was assessed (hydrogen-methane breath test).
With a use of logistic regression it was proved that BMD was dependent upon two
qualitative factors: age (p< 0.03) and body weight (p< 0.04) and one quantitative
factor: lactose malabsorption (p< 0.05). Such a relationship was not documented
for lactase genotype.
In conclusion, lactose malabsorption seems to be an independent risk factor for
decreased BMD in CF children.
310 Bone mineral density measurement in cystic ﬁbrosis patients
with CFTR I1234V mutation in a large kindred family in Qatar
A. Abdul Wahab1, M. Hammoudeh2, M. Alengawi2, F. Kalaf1. 1Hamad Medical
Corporation, Pediatrics, Doha, Qatar; 2Hamad Medical Corporation, Internal
Medicine, Doha, Qatar
Objective: To determine the spectrum of skeletal and prevalence of CF-related low
bone mineral density (BMD) in children and adults with CFTR I1234V mutation
in a large Arab kindred family in Qatar.
Methodology: Twenty-six CF patients aged more than 10 years who attended the
CF clinic at Hamad Medical Corporation between November 2009 till April 2010.
Lumbar spine, total hip, and whole-body bone mineral density were measured by
DEXAscan. Serum Ca, phosphorus, alk. phosphatase, 25-OHD vitamin D, and
vitamin K were measured. Age, gender, BMI, FEV1 and bacterial colonization
were correlated with BMD. The Z score was used for those who were less than
21 years and T score was used in those who were 21 year or older.
Results: Mean age of 17.29±4.95(SE) years, range 10−33 years. All the patients
were pancreatic sufﬁcient.
Mean BMD Z scores for patients 20 years or younger were −0.69±0.96 (L1-
L4), −0.49±0.92 (total hip), and −0.38±0.86 (total body). Mean BMD T scores
for patients 21 years or older were 0.14± 1.13 (L1-L4), 0.38±1 (total hip) and
0.52±1.03 (total body). Seven CF patients had low BMD less than −1 giving
the prevalence of CF-related low BMD of 26.9%. BMI correlated with BMD
lumbar and total body Z or T scores but no signiﬁcant correlation with hip Z
or T score. Vitamin D deﬁciency was found in 20 CF patients (76.9%). BMD was
not signiﬁcantly correlated with gender, Pseudomonas aeruginosa and FEV1.
Conclusion: CF-related low BMD does occur in patients with mild CFTR mutation
associated with pancreatic sufﬁcient. A larger study in a cohort of CF patients in
the Arabian gulf region is required to determine the risk factors of CF-related bone
disease
